Recent Advances in the Diagnosis and Treatment of Niemann-Pick Disease Type C in Children: A Guide to Early Diagnosis for the General Pediatrician

Abstract EN

Niemann-Pick disease (NP-C) is a lysosomal storage disease in which impaired intracellular lipid transport leads to accumulation of cholesterol and glycosphingolipids in various neurovisceral tissues.

It is an autosomal recessive disorder, caused by mutations in the NPC1 or NPC2 genes.

The clinical spectrum is grouped by the age of onset and onset of neurological manifestation: pre/perinatal; early infantile; late infantile; and juvenile periods.

The NP-C Suspicion Index (SI) screening tool was developed to identify suspected patients with this disease.

It is especially good at recognizing the disease in patients older than four years of age.

Biochemical tests involving genetic markers and Filipin staining of skin fibroblast are being employed to assist diagnosis.

Therapy is mostly supportive and since 2009, the first specific therapy approved for use was Miglustat (Zavesca) aimed at stabilizing the rate of progression of neurological manifestation.

The prognosis correlates with age at onset of neurological signs; patients with early onset form progress faster.

The NP-C disease has heterogeneous neurovisceral manifestations.

A SI is a screening tool that helps in diagnostic process.

Filipin staining test is a specific biomarker diagnostic test.

Miglustat is the first disease-specific therapy.